Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity

42Citations
Citations of this article
56Readers
Mendeley users who have this article in their library.

Abstract

Clinical effectiveness of imatinib mesylate in cancer treatment is compromised by its off-target cardiotoxicity. In the present study, we have developed physically stable imatinib mesylate-loaded poly(lactide-co-glycolide) nanoparticles (INPs) that could sustainably release the drug, and studied its efficacy by in vitro anticancer and in vivo cardiotoxicity assays. MTT (methylthiazolyldiphenyl-tetrazolium bromide) assay revealed that INPs are more cytotoxic to MCF-7 breast cancer cells compared to the equivalent concentration of free imatinib mesy-late. Wistar rats orally administered with 50 mg/kg INPs for 28 days showed no significant cardiotoxicity or associated changes. Whereas, increased alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase levels, and reduced white blood cell, red blood cell, and hemoglobin content were observed in the animals administered with free drug. While the histological sections from hearts of animals that received INPs did not show any significant cardiotoxic symptoms, loss of normal architecture and increased cytoplasmic vacuolization were observed in the heart sections of animals administered with free imatinib mesylate. Based on these results, we conclude that nano-encapsulation of imatinib mesylate increases its efficacy against cancer cells, with almost no cardiotoxicity.

Cite

CITATION STYLE

APA

Marslin, G., Revina, A. M., Khandelwal, V. K. M., Balakumar, K., Prakash, J., Franklin, G., & Sheeba, C. J. (2015). Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity. International Journal of Nanomedicine, 10, 3163–3170. https://doi.org/10.2147/IJN.S75962

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free